Phase 1/2 Study of RTX-240 as a Monotherapy and in Combination with Pembrolizumab (RTX-240-01)
Study of RTX-240 in Adults with Relapsed/Refractory or Locally Advanced Solid Tumors
Sponsor: Rubius Therapeutics
Enrolling: Male and Female Patients
IRB Number: AAAS9104
U.S. Govt. ID: NCT04372706
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectiveness of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating your cancer, how much needs to be given for it to work and how often it should be given. The study drug will be administered through IV and the time frame for the study will vary based on the response to treatment. The study drug is made of red blood cells from universal blood donors and changed in a laboratory to express certain proteins, which may stimulate the immune system to attack cancer cells. Cancers include: Bladder cancer, breast cancer, colon cancer, rectal cancer, esophageal cancer, cervical cancer, ovarian cancer, uterine cancer, head and neck/oral cancers, kidney cancer, adrenal cancer, liver cancer, lung cancer, Non-Hodgkin's Lymphoma, skin cancer, melanoma, pancreatic cancer, prostate cancer, sarcomas, stomach cancer, and thyroid cancer.
This study is closed
Mark Stein, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have a solid tumor for which no standard therapy exists? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator